To appraise the clinical and cost effectiveness of sacituzumab govitecan within its marketing authorisation for treating unresectable locally advanced or metastatic triple-negative breast cancer after two or more therapies.
 
Status In progress
Decision Selected
Process STA 2018
ID number 3942

Provisional Schedule

Expected publication 17 August 2022

Project Team

Project lead Rebecca Richardson

Email enquiries

External Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick

Stakeholders

Companies sponsors Gilead Sciences
Others Department of Health and Social Care
  NHE England and NHS Improvement
  Welsh Government
Patient carer groups Breast Cancer Now
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Comparator companies Eisai
General commentators All Wales Therapeutics and Toxicology Centre
  BNF
  Department of Health, Social Services and public Safety - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
14 July 2022 - 28 July 2022 Final draft guidance: 1
07 June 2022 Committee meeting: 2
07 April 2022 - 29 April 2022 Draft guidance: 1
27 April 2022 Due to the number of topics on the agenda for the 10 May 2022 meeting and to allow a fuller discussion of the response to consultation, we have decided to reschedule the discussion of this topic to 7 June 2022. The Project team will contact you with details of how to register for the June meeting in due course
15 March 2022 Committee meeting: 1
17 August 2021 Invitation to participate
08 June 2021 - 06 July 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
30 January 2018 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual